Thus, the absence of secondary tumors, extensive tumor tissue decay and immune cell infiltration, the reduction of cell proliferation rate, and amount of reactive astrocytes, indicated by low levels of GFAP, allow us to conclude that the effectiveness of the oncolytic virus is increased with intratumoral administration of the drug compared to intravenous administration to animals. This evidence concerns the gene GFAP and neoplasm.